NASDAQ:ADIL   Adial Pharmaceuticals, Inc
10:09 AM EDT, 09/11/2019 (MT Newswires) -- Adial Pharmaceuticals (ADIL) said Wednesday that it has successfully retested a previously manufactured supply of clinical trial packaged tablets of the investigational drug AD04 for the treatment of alcohol use disorder.

The company said tests showed that the clinical trial materials passed reevaluation and are eligible for use in the phase 3 trial.

The company has great information about it on their website with promising statisics.

면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.